Acumen Pharmaceuticals (ABOS) Equity Ratio (2020 - 2026)

Acumen Pharmaceuticals' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.65 for Q1 2026.

• In Q1 2026, Equity Ratio fell 13.93% year-over-year to 0.65; the TTM figure through Mar 2026 stood at 0.65 (down 13.93% YoY), while the FY2025 annual figure was 0.57, down 24.63% from the prior year.
• Equity Ratio came in at 0.65 for Q1 2026 at Acumen Pharmaceuticals, up from 0.57 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.57 in Q4 2025.
• A 5-year average of 0.84 and a median of 0.86 in 2023 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio surged 167.09% in 2022 and slipped 24.63% in 2025, its largest moves.
• Acumen Pharmaceuticals' Equity Ratio stood at 0.96 in 2022, then fell by 10.35% to 0.86 in 2023, then slipped by 11.63% to 0.76 in 2024, then retreated by 24.63% to 0.57 in 2025, then advanced by 14.17% to 0.65 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.65, 0.57, and 0.66 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison